GlassScriptPhysician profile
Haley Brooke Pongetti
NPI 1053949008
$3,167.80
in general payments reported to CMS, 2019-2025
38 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $577 · 2022: $613 · 2023: $805 · 2024: $864 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $466.93 | 2021-2025 | Emgality, Amyvid, Kisunla |
| Abbvie INC. | $296.50 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $250.21 | 2023-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $199.55 | 2022-2024 | Xcopri |
| Lundbeck LLC | $199.19 | 2022-2025 | Vyepti |
| Eisai INC. | $179.53 | 2022-2025 | |
| Biogen, INC. | $144.19 | 2021-2025 | Leqembi |
| Pfizer INC. | $127.27 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $93.86 | 2023-2024 | Ztlido |
| Horizon Therapeutics Plc | $91.48 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $90.19 | 2022-2025 | Ultomiris |
| Upsher-Smith Laboratories LLC | $84.58 | 2021 | |
| Acorda Therapeutics, INC | $79.46 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $75.05 | 2023 | Nuedexta |
| Grifols USA, LLC | $65.70 | 2021-2025 | Gamunex-C |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $59.76 | 2022-2023 | Ponvory |
| Teva Pharmaceuticals USA, INC. | $57.44 | 2022 | |
| Banner Life Sciences, LLC | $51.24 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $50.47 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $46.89 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $46.69 | 2021 | |
| Ucb, INC. | $43.38 | 2021 | |
| Argenx US, INC. | $43.18 | 2024-2025 | Vyvgart |
| Csl Behring | $41.31 | 2021 | |
| Jazz Pharmaceuticals INC. | $40.00 | 2023 | |
| Kyowa Kirin, INC. | $37.36 | 2023 | Nourianz |
| Acadia Pharmaceuticals INC | $24.57 | 2022 | |
| Averitas Pharma INC. | $23.95 | 2024 | Qutenza |
| Amgen INC. | $18.33 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $17.97 | 2021 | |
| Celgene Corporation | $17.60 | 2022 | |
| Boston Scientific Corporation | $16.81 | 2025 | Wavewriter Alpha Prime 16 |
| Sobi, INC | $15.95 | 2021 | |
| Tanabe Pharma America, INC. | $15.14 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.03 | 2021 | |
| Currax Pharmaceuticals LLC | $15.03 | 2023 | Onzetra Xsail |
| Sunovion Pharmaceuticals INC. | $13.12 | 2021 | |
| Almatica Pharma LLC | $12.89 | 2023 | Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Pongetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.